-

Kallisio Announces Clinical Implementation of Its Patient-Specific Stentra™ System

BALTIMORE--(BUSINESS WIRE)--Kallisio, a company developing patient-specific precision-therapy solutions, announced that it has collaborated with Stanford Health Care to support the clinical implementation of its FDA-cleared Stentra system for use in head and neck cancer radiation therapy.

As part of this collaboration, Stanford Health Care has incorporated Stentra into its clinical workflow for select head and neck cancer cases.

Share

Stentra is a patient-specific intraoral positioning system designed to support consistent immobilization during external beam radiation therapy. The system produces customized devices based on patient anatomy to assist with tongue and soft tissue positioning during treatment planning and daily radiation delivery.

As part of this collaboration, Stanford Health Care has incorporated Stentra into its clinical workflow for select head and neck cancer cases. The implementation reflects interest in evaluating tools that support reproducible setup and integration within existing radiation oncology processes.

Stentra is designed to be used during CT simulation and throughout the course of radiation therapy. Devices are manufactured using patient-specific digital workflows and are delivered for clinical use within standard treatment timelines. The system is intended to support geometric consistency during treatment while maintaining patient tolerance.

Kallisio’s broader clinical experience with Stentra across multiple institutions has focused on workflow integration, device reproducibility, and patient acceptance within routine radiation oncology operations.

About Kallisio

Kallisio develops patient-specific solutions designed to support precision radiation therapy. The company focuses on scalable, technology-enabled workflows that integrate digital design, manufacturing, and clinical processes to deliver individualized devices for oncology care. Kallisio works with clinical partners to evaluate and implement tools intended to support consistent treatment delivery and reduce variability in radiation therapy. Discover more at kallisio.com.

Contacts

Nicole E. Martin
nicole@kallisio.com
+1.415.860.9194

Kallisio


Release Versions

Contacts

Nicole E. Martin
nicole@kallisio.com
+1.415.860.9194

Social Media Profiles
More News From Kallisio

Texas Cancer Institute Adopts Kallisio’s Patient-Specific Stentra™ Oral Immobilization Solution as Standard-of-Care Following Successful Pilot

BALTIMORE--(BUSINESS WIRE)--Kallisio announces TCI in Austin, Texas has adopted patient-specific Stentra™ for improved head and neck cancer radiation therapy....

Kallisio Stentra™ Named “Best New Radiology Technology Solution” in 2026 MedTech Breakthrough Awards Program

BALTIMORE--(BUSINESS WIRE)--Kallisio announces Stentra™ custom oral immobilization solution for head and neck cancer therapy is named “Best New Radiology Technology Solution”...

Kallisio Receives CE Mark for Stentra™ Precision Oral Immobilization System

BALTIMORE--(BUSINESS WIRE)--Kallisio has received CE certification for its Stentra™ oral immobilization system designed for precise, repeatable head and neck radiation therapy....
Back to Newsroom